Research Analysts Issue Forecasts for SGMO FY2030 Earnings

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) – Investment analysts at HC Wainwright issued their FY2030 earnings estimates for shares of Sangamo Therapeutics in a research note issued to investors on Tuesday, February 10th. HC Wainwright analyst P. Trucchio anticipates that the biopharmaceutical company will post earnings per share of $0.67 for the year. HC Wainwright currently has a “Buy” rating and a $10.00 price target on the stock. The consensus estimate for Sangamo Therapeutics’ current full-year earnings is ($0.46) per share.

A number of other analysts have also weighed in on SGMO. Weiss Ratings reiterated a “sell (e+)” rating on shares of Sangamo Therapeutics in a research note on Thursday, January 22nd. Wall Street Zen downgraded Sangamo Therapeutics to a “strong sell” rating in a research report on Saturday, January 31st. Finally, Barclays reiterated an “equal weight” rating and set a $1.00 price objective (down previously from $5.00) on shares of Sangamo Therapeutics in a research note on Friday, November 7th. One research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $4.33.

Sangamo Therapeutics Trading Up 0.3%

Shares of NASDAQ:SGMO opened at $0.39 on Wednesday. Sangamo Therapeutics has a twelve month low of $0.35 and a twelve month high of $1.24. The company has a market cap of $131.67 million, a PE ratio of -0.89 and a beta of 1.28. The company’s 50 day moving average is $0.43 and its 200 day moving average is $0.51.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. grew its holdings in shares of Sangamo Therapeutics by 23.9% during the 3rd quarter. Vanguard Group Inc. now owns 11,615,150 shares of the biopharmaceutical company’s stock worth $7,817,000 after purchasing an additional 2,240,422 shares during the period. Wasatch Advisors LP grew its stake in Sangamo Therapeutics by 17.7% during the 2nd quarter. Wasatch Advisors LP now owns 8,084,419 shares of the biopharmaceutical company’s stock worth $4,376,000 after purchasing an additional 1,215,653 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of Sangamo Therapeutics by 17.6% during the fourth quarter. Geode Capital Management LLC now owns 3,866,026 shares of the biopharmaceutical company’s stock worth $1,624,000 after purchasing an additional 579,550 shares in the last quarter. GSA Capital Partners LLP raised its position in shares of Sangamo Therapeutics by 63.1% during the 3rd quarter. GSA Capital Partners LLP now owns 3,662,478 shares of the biopharmaceutical company’s stock worth $2,466,000 after acquiring an additional 1,417,029 shares in the last quarter. Finally, Two Sigma Investments LP boosted its holdings in shares of Sangamo Therapeutics by 182.7% in the 3rd quarter. Two Sigma Investments LP now owns 2,479,186 shares of the biopharmaceutical company’s stock valued at $1,669,000 after buying an additional 1,602,107 shares in the last quarter. 56.92% of the stock is currently owned by institutional investors and hedge funds.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc is a clinical-stage biotechnology company headquartered in Brisbane, California, that specializes in the development of genomic therapies based on its proprietary zinc finger nuclease (ZFN) technology. Founded in 1995, Sangamo pioneered ZFN-based genome editing to precisely alter DNA sequences for the treatment of serious genetic and rare diseases. The company’s platform encompasses in vivo genome editing, ex vivo cell therapy, and genome regulation approaches, with a focus on durable therapeutic effects through permanent genetic modification or sustained gene expression control.

Through its genome editing programs, Sangamo is advancing multiple product candidates into clinical trials for conditions such as hemophilia A and B, mucopolysaccharidosis types I and II, and lysosomal storage disorders.